// App-Quantinova.ai

2463 : PEGPH20 increases the anticancer activity of standard chemotherapy combinations, vincristine (VIN) and D actinomycin (DACT), in a Wilms xenograft model

Researchers

Presenter

  • Jessica Cowell

Principal Investigators

  • Susan J. Zimmerman

  • Mathieu Marrela

  • Ping Jiang

  • Peter J. Houghton

  • Michael J. LaBarre

  • Daniel C. Maneval

  • Curtis B. Thompson

  • Xiaoming Li

Medical Centers

  • Halozyme Therapeutics, San Diego, CA

  • University of Texas Health Science Center San Antonio, San Antonio, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic pancreatic adenocarcinoma

  • Non Small Cell Lung cancer

  • Pancreatic cancer

  • Small cell lung cancer

  • Gastric Cancer

  • Breast cancer

  • Hereditary susceptibility to Wilms tumor 5

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • Hyaluronic acid

Drug/Treatment

  • PEGPH20

  • Dactinomycin Injection

  • Pimonidazole

  • Vincristine

  • Hyaluronic acid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved